On August 22, 2022 Prana Thoracic, Inc., reported that Nucore Medical, Inc., the company’s wholly owned subsidiary has been awarded a $3M grant from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Prana Thoracic is a medical device company developing the first minimally invasive lung tissue excision tool for early interception of lung cancer (Press release, Prana Thoracic, AUG 22, 2022, View Source [SID1234618549]). The CPRIT award will help fund the commercialization of Prana Thoracic’s technology through first-in-human studies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We’re excited to be recognized by CPRIT and believe this award speaks to the potential of Prana Thoracic’s surgical oncology devices. This funding will accelerate our technology to the bedside, enabling us to provide Texans and patients all over the world with a definitive diagnosis of their pulmonary nodules earlier in their patient journey," said Joanna Nathan, CEO and founder of Prana Thoracic.
Lung cancer is the leading cause of cancer death in the U.S., making up almost 25% of all cancer deaths. Most lung cancers are diagnosed late, after the disease has spread, making survival limited. While over 14 million patients in the U.S. each year are eligible for lung cancer screening, less than 5% of these patients are currently undergoing the procedure. With Prana Thoracic’s technology – which is minimally invasive and tissue-sparing – physicians can target nodules that are challenging to sample, leading to definitive diagnosis, and dramatically improving outcomes.
"There has long been a gap between a simple needle biopsy of a nodule deep in the lung and opening the chest to remove a large segment of the lung to help diagnose early lung cancer, particularly when the nodules are very small," Dr. Edward Boyle, MD, founder and one of the inventors of the technology. "As inventors, we partnered with the Johnson & Johnson MedTech Center for Device Innovation to help take this through design and early testing. At this point we are eager to advance the technology through first-in-human studies."